ES2532850T3 - Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso - Google Patents

Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso Download PDF

Info

Publication number
ES2532850T3
ES2532850T3 ES07866446.3T ES07866446T ES2532850T3 ES 2532850 T3 ES2532850 T3 ES 2532850T3 ES 07866446 T ES07866446 T ES 07866446T ES 2532850 T3 ES2532850 T3 ES 2532850T3
Authority
ES
Spain
Prior art keywords
botulinum neurotoxin
treatment
anticancer agent
therapeutic use
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07866446.3T
Other languages
English (en)
Inventor
Christine Favre
Michel Auguet
Pierre-Etienne Chabrier De Lassauniere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of ES2532850T3 publication Critical patent/ES2532850T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización de al menos una neurotoxina botulínica para la obtención de un medicamento destinado a tratar o prevenir el o los dolores post-quimioterapia mediante administración localizada por vía intramuscular, intradérmica o subcutánea que permite obtener un efecto generalizado, no siendo el o los dolores dolor(es) inducido(s) por tumores.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES07866446.3T 2006-10-27 2007-10-26 Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso Active ES2532850T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0609435A FR2907680B1 (fr) 2006-10-27 2006-10-27 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR0609435 2006-10-27
PCT/FR2007/001773 WO2008059126A1 (fr) 2006-10-27 2007-10-26 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux

Publications (1)

Publication Number Publication Date
ES2532850T3 true ES2532850T3 (es) 2015-04-01

Family

ID=38109619

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07866446.3T Active ES2532850T3 (es) 2006-10-27 2007-10-26 Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso

Country Status (12)

Country Link
US (1) US8273359B2 (es)
EP (1) EP2083837B1 (es)
JP (1) JP5386359B2 (es)
CN (1) CN101541336B (es)
CA (1) CA2667128C (es)
DK (1) DK2083837T3 (es)
ES (1) ES2532850T3 (es)
FR (1) FR2907680B1 (es)
PL (1) PL2083837T3 (es)
PT (1) PT2083837E (es)
RU (1) RU2483747C2 (es)
WO (1) WO2008059126A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
FR2889936B1 (fr) * 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
EP2085093B1 (en) * 2006-10-27 2015-02-25 The Chemo-Sero-Therapeutic Research Institute Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100332337A1 (en) * 2009-06-25 2010-12-30 Bullock Roddy Mckee Universal one-click online payment method and system
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
ES2642916T3 (es) * 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
JP6808746B2 (ja) 2016-02-19 2021-01-06 アベリー・デニソン・コーポレイションＡｖｅｒｙ Ｄｅｎｎｉｓｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 接着剤を製造する２段階の方法及び関連組成物
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
EP4790115A2 (en) 2016-10-25 2026-08-12 Avery Dennison Corporation Block polymers with photoinitiator groups in backbone and their use in adhesive compositions
JP7507088B2 (ja) 2017-12-19 2024-06-27 エイブリィ・デニソン・コーポレイション ペンダント官能基の後重合官能化
US20230165812A1 (en) * 2020-02-27 2023-06-01 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434535T2 (de) * 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE19501266A1 (de) * 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
ES2237551T3 (es) 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
KR20030018827A (ko) 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2004075832A2 (en) * 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
WO2004084839A2 (en) * 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
GB2417419A (en) 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
GB2416692A (en) 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
US20090232849A1 (en) * 2005-03-03 2009-09-17 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
WO2006122123A2 (en) * 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
KR100726441B1 (ko) * 2005-11-22 2007-06-11 삼성전자주식회사 현상장치 및 이를 이용한 화상형성장치
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique

Also Published As

Publication number Publication date
RU2483747C2 (ru) 2013-06-10
CN101541336B (zh) 2012-12-19
PL2083837T3 (pl) 2015-06-30
CA2667128A1 (fr) 2008-05-22
JP2010507635A (ja) 2010-03-11
US8273359B2 (en) 2012-09-25
PT2083837E (pt) 2015-03-26
DK2083837T3 (en) 2015-03-23
EP2083837A1 (fr) 2009-08-05
EP2083837B1 (fr) 2015-01-07
WO2008059126A1 (fr) 2008-05-22
HK1137352A1 (en) 2010-07-30
RU2009120021A (ru) 2010-12-10
FR2907680A1 (fr) 2008-05-02
FR2907680B1 (fr) 2012-12-28
CA2667128C (fr) 2017-08-29
JP5386359B2 (ja) 2014-01-15
US20100068231A1 (en) 2010-03-18
CN101541336A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
BR112021016169A2 (pt) Composições compreendendo 5-metóxi-n,n-dimetiltriptamina (5-meo-dmt) para uso no tratamento de transtornos mentais
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX362693B (es) Composición para el cuidado oral para tratar y/o prevenir afecciones causadas por microorganismos, usando un dispositivo oral de luz.
AR068862A1 (es) Terapia de combinacion de un anticuerpo anti- cd20 de tipo ii con un agente activo anti- bcl-2
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
ECSP109934A (es) Compuesto - 946
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR105712A1 (es) Composiciones de insulina de rápida acción
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
ES2604586T3 (es) Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética
AR090999A1 (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2008003022A1 (es) Composicion farmaceutica que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-{1,3,4-oxadiazol-2-il}fenil)piridin-3-sulfonamida con manitol y celulosa microcristalina; y uso para el tratamiento del cancer de prostata, de ovario y de vejiga, entre otros.
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular